Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development

被引:58
作者
Rolan, P
Atkinson, AJ
Lesko, LJ
机构
[1] Medeval Ltd, Manchester M15 6SH, Lancs, England
[2] NIH, Ctr Clin, Bethesda, MD 20892 USA
[3] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
关键词
D O I
10.1016/S0009-9236(02)17625-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Ninth European Federation for Pharmaceutical Sciences (EUFEPS) Conference on Optimizing Drug Development was held in Basel, Switzerland, December 10-12, 2001. The overall objective of the conference was to find new ways of advancing the integration of biomarkers into drug development and clinical practice to make drug development more efficient and the clinical use of drugs more effective. The aim of this conference report is to summarize the key ideas and recommendations that were identified at the meeting, both by formal presentation and from the breakout sessions, which all participants were encouraged to join. Rather than providing a synopsis of each individual presentation, the report is organized along the key themes that emerged during the meeting.
引用
收藏
页码:284 / 291
页数:8
相关论文
共 22 条
[1]   New insights into cyclosporine A nephrotoxicity by proteome analysis [J].
Aicher, L ;
Wahl, D ;
Arce, A ;
Grenet, O ;
Steiner, S .
ELECTROPHORESIS, 1998, 19 (11) :1998-2003
[2]   Future chips - Micromachines - Fomenting a revolution, in miniature [J].
Amato, I .
SCIENCE, 1998, 282 (5388) :402-+
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Hepatotoxicity in drug development: Detection, significance and solutions [J].
Ballet, F .
JOURNAL OF HEPATOLOGY, 1997, 26 :26-36
[5]  
Bichsel VE, 2001, CANCER J, V7, P69
[6]   Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development - The 'Wooden Shoe' paradigm [J].
Breimer, DD ;
Danhof, M .
CLINICAL PHARMACOKINETICS, 1997, 32 (04) :259-267
[7]   Heart failure 99 - the Moxcon story [J].
Coats, AJS .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1999, 71 (02) :109-111
[8]   Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop [J].
De Gruttola, VG ;
Clax, P ;
DeMets, DL ;
Downing, GJ ;
Ellenberg, SS ;
Friedman, L ;
Gail, MH ;
Prentice, R ;
Wittes, J ;
Zeger, SL .
CONTROLLED CLINICAL TRIALS, 2001, 22 (05) :485-502
[9]   MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].
ECHT, DS ;
LIEBSON, PR ;
MITCHELL, LB ;
PETERS, RW ;
OBIASMANNO, D ;
BARKER, AH ;
ARENSBERG, D ;
BAKER, A ;
FRIEDMAN, L ;
GREENE, HL ;
HUTHER, ML ;
RICHARDSON, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788
[10]   Cybernetic cells [J].
Gibbs, WW .
SCIENTIFIC AMERICAN, 2001, 285 (02) :52-57